Skip to content

Organon OGN Debt Issuance Proceeds

Debt Issuance Proceeds at other companies

Amgen logo
AmgenAMGN
$3.96B
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
$857.7M+14.6%
AbbVie logo
AbbVieABBV
$7.99B+100%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$134.67M
PBH
Prestige Consumer HealthcarePBH
$10M
Abbott logo
AbbottABT
$19.86B+1,985,900%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%
Debt / equity9.5×-7.0×
Current ratio+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfLongTermDebt.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's debt issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's debt issuance proceeds?
Organon (OGN) reported debt issuance proceeds of $0 in Q1 2026.
How has Organon's debt issuance proceeds changed year-over-year?
Organon's debt issuance proceeds decreased by 100.0% year-over-year, from $90M to $0.
What is the long-term trend for Organon's debt issuance proceeds?
Over 3 years (2021 to 2025), Organon's debt issuance proceeds has grown at a -51.9% compound annual growth rate (CAGR), from $9.47B to $1.06B.
What does debt issuance proceeds mean?
Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.